Sialidase-Conjugated "NanoNiche" for Efficient Immune Checkpoint Blockade Therapy

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Immune checkpoint blockade, particularly targeting PD-1/PD-L1, shows promise in cancer treatment.
• N-linked glycosylation of PD-L1 can hinder antibody recognition and therapeutic efficacy.

Purpose of the Study:

• To develop an effective strategy for blocking PD-1/PD-L1 interactions.
• To enhance T-cell immunity and antitumor effects using a novel conjugate.

Main Methods:

• Development of a sialidase-conjugated NanoNiche that molecularly imprints PD-L1 N-glycans.
• NanoNiche specifically recognizes and blocks glycosylated PD-L1 on tumor cells.
• Sialidase activity on NanoNiche removes sialoglycans, promoting immune cell infiltration.

Main Results:

• In vitro studies confirmed NanoNiche's specific binding to PD-L1 and desialylation of tumor cells.
• NanoNiche treatment significantly inhibited the proliferation of PD-L1-positive breast cancer cells under T-cell killing.
• In vivo experiments demonstrated enhanced therapeutic efficacy in solid tumors.

Conclusions:

• The NanoNiche-sialidase conjugate offers an effective approach for PD-L1 blockade.
• This strategy enhances T-cell reactivation and antitumor immunity.
• Represents a promising advancement in immune checkpoint blockade therapy for cancer.